The Blood-Brain Barrier Has Been Breached. Is Clinical Trial Science Ready?
FDA's March 2026 approval of AVLAYAH marks the first BBB-crossing biologic — but CNS trial design, PK monitoring, and...
Arletta Pharma Advances Lybrido for Female Sexual Desire Disorder With FDA Backing
Arletta Pharma's Lybrido for female sexual desire disorder advances with FDA backing for a single-trial Phase 3 pathway.
Ambient AI Is Not Losing Your Trial Data. It’s Quietly Deciding What Counts.
Ambient AI scribes reduce physician burnout—but a Lancet case reveals they systematically drop psychosocial context that drives protocol adherence...
Neurizon Completes NUZ-001 ALS Trial Enrollment, Advances Results to Q2 2027
Neurizon completes NUZ-001 ALS Trial enrollment of 250 patients in five months, with topline results expected in late Q2...
FDA Clears IND for Umoja’s UB-VV400 In Vivo CAR T Therapy
FDA clears IND for Umoja's in vivo CAR T therapy UB-VV400, targeting relapsed B cell malignancies with a single...
The Bispecific Combination Wave Is Here: What the Englumafusp-Glofitamab Trial Signals for Hematology Trial Design
A Phase 1 trial pairing englumafusp alfa with glofitamab in B-cell NHL reveals a mechanistic shift reshaping how sponsors...
After EVAR, the Aneurysm Sac Remains. Shape Memory Medical Is Running the First Randomized Pivotal Trial to Do Something About It.
With enrollment complete at 48 centers across three countries, CEO Ted Ruppel and VP of Marketing Mary Dennehy explain...
RT-114 Achieves Oral Bioavailability Exceeding Subcutaneous Dose in Phase 1a
RT-114 oral bioavailability exceeded subcutaneous dosing by over 150% in Phase 1a, marking a significant advance for GLP-1 delivery.
Allogene’s ALLO-316 Achieves 31% Response Rate in Advanced Renal Cell Carcinoma
ALLO-316 achieves 31% response rate in advanced renal cell carcinoma patients previously resistant to checkpoint inhibitors and tyrosine kinase...
![Stack of documents clipped with a black binder clip on a wooden desk, with a pen and glasses nearby in sunlight] ,](https://www.clinicaltrialvanguard.com/wp-content/uploads/2026/07/your-recruitment-plan-is-failing-before-screening-even-start-750x575.png)
Your Recruitment Plan Is Failing Before Screening Even Starts
59% of sites report recruitment blocked by process inefficiencies—the bottleneck isn't patient supply, it's the workflow that never gets...